Mimetic of a peptide that is a ripening product of the basic proline lacrimal protein (BPLP) or a peptide derivative of said ripening product, in which: (i) the peptide or peptide derivative has an inhibitory property against a metalloectopeptidase； (ii) the peptide or peptide derivative is a maximum of 15 amino acids in length； (iii) the peptide comprises the sequence X1-X2-Arg-Phe-Ser-Arg, in which: - X1 represents an atom of H, - X2 represents Gln or Glp, wherein said sequence X1-X2-Arg- Phe-Ser-Arg is the C-end part of said peptide； and (iv) the peptide derivative is derived from said peptide by one to two amino acid substitutions； and wherein the mimetic retains the specificity of binding and / or the physiological activity of said peptide or peptide derivative； wherein the BPLP protein consists of SEQ ID NO: 2； wherein a BPLP maturation product is a peptide obtained through cleavage of the BPLP protein by natural maturates or prohormone converting enzymes, or enzymes that cleave basic single or related matched amino acids, and in which said mimetic is obtained (i) by substitution of one or more amide bonds with a non-amide bond, (ii) by substitution of one or more amino acid side chains by a different chemical group, (iii) protecting one or more of the N-terminus, the C-terminus or one or more side chains with a protective group, (iv) introducing double bonds and / or cyclisation and / or stereospecificity in the amino acid chain to increase stiffness and / or binding affinity, (v) through the development of designs of computer-assisted drugs, (vi) protecting the NH2 and COOH hydrophilic groups by esterification (COOH) with lipophilic alcohols or by amidation (COOH) and / or by acetylation or addition of hydrophobic car chain boxylalkyl or aromatic at the NH2 end, (vii) by isomeric retroversion of the CO-NH amide bonds or methylation of the amide functions, or (viii) by substitution of L-amino acids with D-amino acids, or (ix) by isosteric substitution .Miméti
